The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo-controlled trial

Clinical Psychopharmacology and Neuroscience

Volumn 9, Issue 2, 2011, Pages 73-77

  Lee, Jieun ^a   Sung, Joon Cho ^a   Kang, Soo Lee ^b   Yook, Keunyoung ^a   Ah, Young Choe ^a   Lee, Sungjae ^a   Kim, Borah ^a   Kim, Keung Hyang ^a   Tae, Kyou Choi ^a   Lee, Sang Hyuk ^a  

^a CHA University   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

Author keywords

Augmentation; Mirtazapine; Risperidone; Schizophrenia; Tolerability

Indexed keywords

MIRTAZAPINE; PLACEBO; RISPERIDONE;

ADULT; AGITATION; BARNES AKATHISIA RATING SCALE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG POTENTIATION; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; MALE; MUSCLE TWITCH; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PREMATURE EJACULATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPSOM ANGUS SCALE; WEAKNESS; WEIGHT GAIN;

EID: 80052564386     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: 10.9758/cpn.2011.9.2.73     Document Type: Review

References (19)

1. Kasper S. Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10 Suppl 4:25-35. (Pubitemid 26059120)
2. Montgomery S.A. Safety of mirtazapine: A review. Int Clin Psychopharmacol 1995;10 Suppl 4:37-45. (Pubitemid 26058318)
3. Berk M., Gama C.S., Sundram S., Hustig H., Koopowitz L., D'Souza R., et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 2009;24:233-238.
4. Joffe G., Terevnikov V., Joffe M., Stenberg J.H., Burkin M., Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial. Schizophr Res 2009;108:245-251.
5. Cho S.J., Yook K., Kim B., Choi T.K., Lee K.S., Kim Y.W., et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:208-211.
6. Abbasi S.H., Behpournia H., Ghoreshi A., Salehi B., Raznahan M., Rezazadeh S.A., et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. Schizophr Res 2010;116:101-106.
7. Hieber R., Dellenbaugh T., Nelson L.A. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008;42:841-846. (Pubitemid 351778091)
8. Poyurovsky M., Epshtein S., Fuchs C., Schneidman M., Weizman R., Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003;23:305-308. (Pubitemid 36807796)
9. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992;49:624-629.
10. Guy W. Patient assessment in clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:601-606. (Pubitemid 13146295)
11. Barnes T.R. The Barnes Akathisia Rating Scale--revisited. J Psychopharmacol 2003;17:365-370.
12. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
13. Sachdev P. A rating scale for acute drug-induced akathisia: Development, reliability, and validity. Biol Psychiatry 1994;35:263-271. (Pubitemid 24118458)
14. Owens DGC. A guide to the extrapyramidal side-effects of antipsychotic drugs [dissertation]. Cambridge: Cambridge University Press;1999.
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276. (Pubitemid 18039085)
16. Vanderkooy J.D., Kennedy S.H., Bagby R.M. Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002;47:174-180. (Pubitemid 34464559)
17. Ranjan S., Chandra P.S., Chaturvedi S.K., Prabhu S.C., Gupta A. Atypical antipsychotic-induced akathisia with depression: Therapeutic role of mirtazapine. Ann Pharmacother 2006;40:771-774.
18. Berendsen H.H., Broekkamp C.L., Pinder R.M. Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats. Psychopharmacology (Berl) 1998;135:284-289. (Pubitemid 28055464)
19. Ackerman S., Nolan L.J. Bodyweight gain induced by psychotropic drugs. Incidence, mechanisms and management. CNS Drugs 1998;9:135-151. (Pubitemid 28101535)